|Day's Range||0.0295 - 0.0310|
|52 Week Range||0.0110 - 0.3300|
|PE Ratio (TTM)||-0.33|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Click here to see latest analysisProvectus Biopharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2016.AnalysisSummary numbers: Revenues of USD 0 million, Net Earnings of USD -8.51 million.The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.PVCT-US‘s earnings and EBITDA are […] (Read more...) The post Provectus Biopharmaceuticals, Inc. :PVCT-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 appeared first on CapitalCube.
The extravagant travel-expense payouts to Provectus CEO Craig leaves the company at risk of criminal or civil investigations by the Securities and Exchange Commission.
Modern cancer drugs supercharge immune systems, target specific gene mutations and pack modified viruses into vaccines. Rose Bengal, a cheap industrial chemical that turns yarn and food bright red, has been used as a diagnostic staining agent for some time. Now, some scientists are looking at its potential to fight various forms of cancer.